The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Value of 18F-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy
Open accessAbstract
Purpose: To determine the value of combined positron emission tomography/computed tomography (PET/CT) during induction chemotherapy (CTx) followed by chemoradiotherapy (CTx/RTx) for non–small-cell lung cancer to predict histopathologic response in primary tumor and mediastinum and prognosis of the patient. Experimental Design: Fifty consecutive patients with locally advanced non–small-cell lung cancer received induction therapy and, if considered resectable, proceeded to surgery (37 of 50 patients). Patients had at least two repeated 18F-2-fluoro-2-deoxy-d-glucose (FDG)-PET/CT scans either before treatment (t0) or after induction CTx (t1) or CTx/RTx (t2). Variables from the PET/CT studies [e.g., lesion volume and corrected maximum standardized glucose uptake values (SUVmax,corr)] were correlated with histopathologic response (graded as 3, 2b, or 2a: 0%, >0-10%, or >10% residual tumor cells) and times to failure. Results: Primary tumors showed a percentage decrease in SUVmax,corr during induction significantly larger in grade 2b/3 than in grade 2a responding tumors (67% versus 34% at t1, 73% versus 49% at t2; both P < 0.005). SUVmax,corr at t2 was significantly correlated with histopathologic response in tumors smaller than the median volume (7.5 cm3; r = −0.54, P = 0.02). In the mediastinal lymph nodes, SUVmax,corr values at t2 predicted an ypN0 status with a sensitivity and specificity of 73% and 89%, respectively (SUVmax,corr threshold of 4.1, r = −0.54, P = 0.0005). Freedom from extracerebral relapse was significantly better in grade 2b/3 patients (86% at 16 months versus 20% in 2a responders; P = 0.003) and in patients with a greater percentage decrease in SUVmax,corr in the primary tumor at t2 in relation to t0 than in patients with lesser response (83% at 16 months versus 43%; P = 0.03 for cutoff points between 0.45 and 0.55). Conclusions: SUVmax,corr values from two serial PET/CT scans, before and after three chemotherapy cycles or later, allow prediction of histopathologic response in the primary tumor and mediastinal lymph nodes and have prognostic value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Attenuation correction for a combined 3D PET/CT scanner
Kinahan, P. E., Townsend, D. W., Beyer, T., & Sashin, D. (1998) · Medical Physics · doi:10.1118/1.598392 · Cited by 946
Cited by
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“Studies in which complex partial-volume corrections have been performed in addition to corrections for background spillover from nearby tissues have sometimes, but not consistently, demonstrated quantitation to be superior to visual assessments for predicting response and outcome (136).”
BackgroundGold nanostructures: a class of multifunctional materials for biomedical applications
Cobley, C. M., Chen, J., Cho, E. C., Wang, L. V., & Xia, Y. (2011) · Chem. Soc. Rev. · doi:10.1039/b821763g · Cited by 792
Gold Nanocages as Photothermal Transducers for Cancer Treatment
Chen, J., Glaus, C., Laforest, R., Zhang, Q., Yang, M., Gidding, M., Welch, M. J., & Xia, Y. (2010) · Small · doi:10.1002/smll.200902216 · Cited by 691
De Ruysscher, D., Faivre-Finn, C., Nestle, U., Hurkmans, C. W., Le Péchoux, C., Price, A., & Senan, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3271 · Cited by 364
A Review of Applications of Metabolomics in Cancer
Beger, R. (2013) · Metabolites · doi:10.3390/metabo3030552 · Cited by 288
Metadata
- Authors
- Pöttgen, C., Levegrün, S., Theegarten, D., Marnitz, S., Grehl, S., Pink, R., Eberhardt, W., Stamatis, G., Gauler, T., Antoch, G., Bockisch, A., & Stuschke, M.
- Venue
- Clinical Cancer Research
- Published
- 2006-01-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-106
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2131481219
- Cited by
- 204
- References
- 1
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Value of 18F-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0510
- The paper
- Pöttgen, C., Levegrün, S., Theegarten, D., Marnitz, S., Grehl, S., Pink, R., Eberhardt, W., Stamatis, G., Gauler, T., Antoch, G., Bockisch, A., & Stuschke, M. (2006). Value of 18F-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0510
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.